| Project/Area Number |
07671318
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
MANABE Tadao Nagoya City University Medical School, Professor, 医学部, 教授 (80127141)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIZUNO Isamu Nagoya City University, Medical School, Lecturer, 医学部, 講師 (20157506)
YOTSUYANAGI Toshihisa Nagoya City University, Faculty of Pharmaceutical Sciences, Professor, 薬学部, 教授 (40080189)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1996: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1995: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | carboplatin / alpha-TCP-particles / AH130 carcinoma / controlled release |
|---|
| Research Abstract |
alpha-Tricalcium phosphate (alpha-TCP) is biomaterial and its chemical properties is as similar as hydroxyapatite. It is known that alpha-TCP has excellent compatibility with human tissues and is biodegradable. We usesd alpha-TCP particles as a drug carrier, mixing with 4mg carboplatin (CBDCA) to 200mg alpha-TCP particles, and made the slow relesae drugs : alpha-TCP-CBDCA.
The pharmacokinetics of alpha-TCP-CBDCA were examined using Donryu rat models with AH130 abdominal carcinomatosis. alpha-TCP particles were administered into the peritoneal cavity (i.p.) and were taken up especially in the greater omentum. The Pt levels in ascites and the greater omentum were higher in the alpha-TCP-CBDCA i.p. from 1 to 168 hours than in the CBDCA i.p. and i.v. groups.
alpha-TCP-CBDCA i.p. was effective in prolonging the survival of rats. These results suggest that the efficacy of CBDCA may be enhanced by utilizing alpha-TCP particles as a drug carrier.
|
